Citigroup’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-21,000
| Closed | -$561K | – | 5896 |
|
|
2025
Q4 | $561K | Buy |
+21,000
| New | +$502K | ﹤0.01% | 3518 |
|
|
2025
Q3 | – | Sell |
-59,900
| Closed | -$1.29M | – | 6052 |
|
|
2025
Q2 | $1.29M | Buy |
59,900
+30,000
| +100% | +$558K | ﹤0.01% | 3012 |
|
|
2025
Q1 | $497K | Buy |
+29,900
| New | +$543K | ﹤0.01% | 3682 |
|
|
2024
Q1 | – | Sell |
-27,300
| Closed | -$855K | – | 5612 |
|
|
2023
Q4 | $855K | Buy |
+27,300
| New | +$652K | ﹤0.01% | 2960 |
|
|
2023
Q2 | – | Sell |
-49,800
| Closed | -$937K | – | 5555 |
|
|
2023
Q1 | $937K | Buy |
49,800
+19,800
| +66% | +$377K | ﹤0.01% | 2610 |
|
|
2022
Q4 | $478K | Buy |
+30,000
| New | +$469K | ﹤0.01% | 3211 |
|
|
2022
Q3 | – | Sell |
-25,000
| Closed | -$352K | – | 5772 |
|
|
2022
Q2 | $352K | Buy |
+25,000
| New | +$467K | ﹤0.01% | 3482 |
|
|
2021
Q1 | – | Sell |
-39,200
| Closed | -$2.1M | – | 6155 |
|
|
2020
Q4 | $2.1M | Sell |
39,200
-3,200
| -8% | -$159K | ﹤0.01% | 2806 |
|
|
2020
Q3 | $1.75M | Buy |
42,400
+2,300
| +6% | +$99.3K | ﹤0.01% | 2767 |
|
|
2020
Q2 | $1.94M | Sell |
40,100
-1,500
| -4% | -$72K | ﹤0.01% | 2841 |
|
|
2020
Q1 | $1.76M | Sell |
41,600
-38,200
| -48% | -$1.57M | ﹤0.01% | 2603 |
|
|
2019
Q4 | $3.41M | Buy |
79,800
+11,800
| +17% | +$513K | ﹤0.01% | 2389 |
|
|
2019
Q3 | $2.45M | Sell |
68,000
-2,400
| -3% | -$72.8K | ﹤0.01% | 2643 |
|
|
2019
Q2 | $1.88M | Buy |
70,400
+26,400
| +60% | +$674K | ﹤0.01% | 2933 |
|
|
2019
Q1 | $1.18M | Sell |
44,000
-17,500
| -28% | -$409K | ﹤0.01% | 3217 |
|
|
2018
Q4 | $994K | Buy |
61,500
+21,100
| +52% | +$410K | ﹤0.01% | 3415 |
|
|
2018
Q3 | $839K | Buy |
40,400
+3,500
| +9% | +$55.1K | ﹤0.01% | 3692 |
|
|
2018
Q2 | $563K | Sell |
36,900
-4,100
| -10% | -$73.1K | ﹤0.01% | 3965 |
|
|
2018
Q1 | $921K | Sell |
41,000
-18,200
| -31% | -$504K | ﹤0.01% | 3314 |
|
|
2017
Q4 | $1.78M | Buy |
59,200
+19,500
| +49% | +$624K | ﹤0.01% | 2789 |
|
|
2017
Q3 | $1.5M | Sell |
39,700
-29,200
| -42% | -$950K | ﹤0.01% | 2957 |
|
|
2017
Q2 | $1.92M | Buy |
68,900
+18,200
| +36% | +$542K | ﹤0.01% | 2635 |
|
|
2017
Q1 | $1.74M | Sell |
50,700
-146,300
| -74% | -$5.16M | ﹤0.01% | 2622 |
|
|
2016
Q4 | $5.68M | Buy |
197,000
+125,800
| +177% | +$3.33M | 0.01% | 1696 |
|
|
2016
Q3 | $2.27M | Buy |
71,200
+5,000
| +8% | +$170K | ﹤0.01% | 2401 |
|
|
2016
Q2 | $2.15M | Buy |
66,200
+20,000
| +43% | +$669K | ﹤0.01% | 2286 |
|
|
2016
Q1 | $1.29M | Buy |
46,200
+32,400
| +235% | +$706K | ﹤0.01% | 3028 |
|
|
2015
Q4 | $492K | Buy |
13,800
+6,500
| +89% | +$229K | ﹤0.01% | 3882 |
|
|
2015
Q3 | $241K | Buy |
7,300
+5,900
| +421% | +$245K | ﹤0.01% | 4348 |
|
|
2015
Q2 | $59K | Buy |
+1,400
| New | +$54.2K | ﹤0.01% | 5397 |
|
Other funds holding ACAD
BBA
VPM
RI
VCM
PAI
Citigroup's ACAD Position: Q1 2026 in Review
Citigroup reduced its Acadia Pharmaceuticals (ACAD) stake by 19% in Q1 2026, selling an estimated $387K and leaving 67,487 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2852.
Citigroup first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $36M in Q2 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.
- Citigroup held 67,487 shares of Acadia Pharmaceuticals worth $1.5M as of Q1 2026.
- Citigroup sold 16,197 Acadia Pharmaceuticals shares in Q1 2026, an estimated $387K.
- Acadia Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2852 holding.
- Citigroup first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Acadia Pharmaceuticals position peaked at $36M in Q2 2025.
- 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.